Growth hormone secretory pattern and response to treatment in children with short stature followed to adult height

Radetti, Giorgio; Buzi, Fabio; Cassar, Walburga; Paganini, Chiara; Stacul, Elisabetta; Maghnie, Mohamad

doi:10.1046/j.1365-2265.2003.01773.x

Cited by 23 publications

(29 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Onset of puberty during treatment was not evaluated and could account for much or all of this acceleration. A similar first-year growth acceleration was reported in 2 other studies of children diagnosed by the same criteria [79][80][81] , and both of these studies suffered from the same limitations.…”

Section: (Strong Recommendation ••⚪⚪)supporting

confidence: 60%

“…We could find a report of the effects on AH in only one retrospective study [80] that showed a mean AH gain of 1.03 SDS following GH treatment in children who met the criteria for neurosecretory dysfunction, compared to untreated ISS cases with normal spontaneous secretion. This gain is virtually identical to that obtained in treated ISS (see discussion below) making the contribution of the spontaneous GH measurement very questionable.…”

Section: (Strong Recommendation ••⚪⚪)mentioning

confidence: 99%

See 1 more Smart Citation

Guidelines for Growth Hormone and Insulin-Like Growth Factor-I Treatment in Children and Adolescents: Growth Hormone Deficiency, Idiopathic Short Stature, and Primary Insulin-Like Growth Factor-I Deficiency

DiVall²,

et al. 2016

View full text Add to dashboard Cite

Background/Aims: On behalf of the Drug and Therapeutics, and Ethics Committees of the Pediatric Endocrine Society, we sought to update the guidelines published in 2003 on the use of growth hormone (GH). Because idiopathic short stature (ISS) remains a controversial indication, and diagnostic challenges often blur the distinction between ISS, GH deficiency (GHD), and primary IGF-I deficiency (PIGFD), we focused on these three diagnoses, thereby adding recombinant IGF-I therapy to the GH guidelines for the first time. Methods: This guideline was developed following the GRADE approach (Grading of Recommendations, Assessment, Development, and Evaluation). Results: This guideline provides recommendations for the clinical management of children and adolescents with growth failure from GHD, ISS, or PIGFD using the best available evidence. Conclusion: The taskforce suggests that the recommendations be applied in clinical practice with consideration of the evolving literature and the risks and benefits to each individual patient. In many instances, careful review highlights areas that need further research.

show abstract

Section: (Strong Recommendation ••⚪⚪)supporting

confidence: 60%

Section: (Strong Recommendation ••⚪⚪)mentioning

confidence: 99%

Guidelines for Growth Hormone and Insulin-Like Growth Factor-I Treatment in Children and Adolescents: Growth Hormone Deficiency, Idiopathic Short Stature, and Primary Insulin-Like Growth Factor-I Deficiency

DiVall²,

et al. 2016

View full text Add to dashboard Cite

show abstract

“…W procesie diagnostycznym wykonuje się zazwyczaj dwa testy i ocenia się maksymalne stężenie GH. Obecnie w Polsce i w większości krajów do rozpoznania niedoboru GH przyjmuje się wartość poniżej 10 ng/ml [9][10][11][12][13]. Przy tym za ciężki niedobór GH (sGHD) u dziecka przyjmuje się zazwyczaj maksymalny wyrzut GH poniżej 5 ng/ml, a za częściowy niedobór GH (pGHD) maksymalny wyrzut GH pomiędzy 5 a 10 ng/ml [14][15][16].…”

Section: Wstępunclassified

The Prognostic Value of The Growth Hormone Secretion Stimulating Tests withl-dopa and clonidine in Children with Growth Hormone Deficiency Treated with Recombinant Human Growth Hormone in Western Pomeranian Region

Biczysko-Mokosa¹,

Petriczko²,

Horodnicka‐Józwa³

et al. 2016

Pediatr. Endocrinol.

View full text Add to dashboard Cite

“…Além disso, os critérios diagnósticos utilizados na maior parte das vezes -pico de GH máximo em testes de estímulo < 10 ng/ml -são arbitrários, inespecíficos (33,34), provavelmente inadequados para os ensaios monoclonais atuais (28), além de não necessariamente levarem em consideração os critérios clínicos e auxoló-gicos sabidamente importantes para a definição do diagnóstico de DGH. Sendo assim, diversos autores (8,23,25,34-36) têm apontado evidências de que uma proporção considerá-vel de indivíduos considerados como tendo DGH nesses estudos apresentem na verdade condições como baixa estatura idiopática ou retardo constitucional do crescimento e puberdade, o que prejudica a interpretação dos dados levantados e, conseqüentemente, a qualidade da previsão de resposta.…”

Section: Análise Crítica Dos Modelos Preditivos Atuais Vieses De Seleunclassified

Modelos matemáticos para previsão de resposta ao tratamento com hormônio de crescimento

Costalonga

Jorge

Mendonça

et al. 2008

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

RESUMOModelos preditivos de crescimento são algoritmos derivados de análises de regressão linear múltipla contendo variáveis que influenciam o crescimento em resposta ao tratamento com gH em determinado grupo de indivíduos durante determinado período. A partir do conhecimento da importância relativa de cada variável, são geradas fórmulas matemáticas que permitem obter uma medida objetiva do potencial de crescimento de cada indivíduo em resposta ao tratamento com gH em diferentes situações. tais algoritmos podem, portanto, ser utilizados como ferramentas para a decisão fundamentada em evidência das estratégias de tratamento com gH a serem utilizadas em diferentes crianças com baixa estatura, a fim de se obter o máximo de custoefetividade com a menor dose cumulativa possível. Já foram desenvolvidos diversos modelos de previsão de resposta ao tratamento com gH em diferentes causas de baixa estatura, porém estes ainda apresentam baixa aplicabilidade clínica por causa do baixo poder preditivo e da baixa precisão da previsão, o que tem gerado crescente interesse pela incorporação de variáveis adicionais, como marcadores bioquímicos e genéticos que possam melhorar a acurácia da previsão e, assim, permitir que, no futuro, o tratamento com gH possa ser individualizado conforme as necessidades específicas de cada criança. ABSTRAcTMathematical Models for Predicting Growth Responses to Growth Hormone Replacement Therapy. growth prediction models are algorithms derived from multiple regression analyses including variables that influence growth responses to gH therapy in a defined group of subjects over a defined period of time. Mathematical equations can be derived from the knowledge acquired with the relative importance of each variable, which provide objective measurements of each subject's growth potential in response to gH therapy on different situations. therefore, these equations can be used as tools to improve evidence-based decision regarding to growth promoting treatment strategies to be used in each child, optimizing cost-effectiveness with the lowest cumulative gH dose. several models have already been developed to predict growth responses to gH for different short stature causes, but they still have low clinical usefulness, due to their low predictive power and low prevision accuracy. this has lead to a growing interest in the addition of new variables, such as biochemical or genetic markers, which could improve prevision accuracy and then allow, in the future, gH therapy individualization according to the specific needs of each child.

show abstract

Growth hormone secretory pattern and response to treatment in children with short stature followed to adult height

Abstract: Long-term administration of GH to short children with normal spontaneous GH secretion is not associated with an appreciable increase in adult height.

Cited by 23 publications

References 52 publications

Guidelines for Growth Hormone and Insulin-Like Growth Factor-I Treatment in Children and Adolescents: Growth Hormone Deficiency, Idiopathic Short Stature, and Primary Insulin-Like Growth Factor-I Deficiency

Guidelines for Growth Hormone and Insulin-Like Growth Factor-I Treatment in Children and Adolescents: Growth Hormone Deficiency, Idiopathic Short Stature, and Primary Insulin-Like Growth Factor-I Deficiency

The Prognostic Value of The Growth Hormone Secretion Stimulating Tests withl-dopa and clonidine in Children with Growth Hormone Deficiency Treated with Recombinant Human Growth Hormone in Western Pomeranian Region

Modelos matemáticos para previsão de resposta ao tratamento com hormônio de crescimento

Contact Info

Product

Resources

About